Benitec Biopharma is a clinical-stage biotechnology company focused on the development of genetic medicines. The platform, called DNA-directed RNA interference, combines RNA interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. Co. is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a genetic disorder. BB-301 is an adeno-associated viral vectors -based gene therapy designed to silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD). The BNTC average annual return since 2014 is shown above.
The Average Annual Return on the BNTC average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether BNTC average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the BNTC average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|